Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Synairgen plc (SYGGF)
Southampton, GB
Synairgen plc is a biopharmaceutical company focused on the discovery and advancement of therapeutic drugs for various respiratory conditions. Their product pipeline features SNG001, an inhaled interferon beta under development for the treatment of COVID-19. They are also conducting Phase II clinical trials for an inhaled formulation of interferon beta (IFN-ß), targeting both asthma exacerbated by the common cold and flu, and the treatment or prevention of chronic obstructive pulmonary disease (COPD). Furthermore, Synairgen is developing a LOXL2 inhibitor specifically for idiopathic pulmonary fibrosis (IPF) disease. This LOXL2 inhibitor is being developed through a licensing and collaborative agreement with Pharmaxis Ltd. The company was founded in 2004 and is based in Southampton, United Kingdom.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +900.00% | +0.00% | +900.00% | +0.00% | -99.88% | -100.00% | -100.00% | -100.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+19.1% Q4'24: +32.3% (vs Q4'22)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%-482.8% Q4'24: -1,024.8% (vs Q4'22)
-
Share dilution Biotechnology: -3.4%+0.1% ★ Q4'24: +0.2% (vs Q4'22)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× Q4'24: 0.00× (vs Q4'22)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2017 actual |
Dec 2024 actual |
Dec 2025 actual |
|---|---|---|---|
| Revenue |
5.03M
est: 5.10M (-1.4%)
|
—
|
—
est.
|
| EBITDA |
1.64M
|
-8.29M
|
—
est.
|
| EBIT |
1.62M
|
-8.32M
|
—
est.
|
| Net Income |
1.76M
est: -1.38M (+227.6%)
|
-6.81M
est: -6.01M (-13.4%)
|
-3.00M
est.
|
| SGA |
1.35M
|
2.72M
|
—
est.
|
| EPS |
0.02
est: -0.01 (+380.5%)
|
-0.03
est: -0.03 (-13.5%)
|
-0.01
est.
|
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Joseph Tregonning Colliver | Chief Executive Officer & Executive Director | 265.6K | male |
| Ratko Djukanovic | Co-Founder & Member of Scientific Advisory Board | 53.8K | — |
| Donna Davies | Co-Founder & Member of Scientific Advisory Board | 53.8K | — |
| Stephen T. Holgate | Co-Founder & Member of Scientific Advisory Board | 53.8K | — |
| Mark Parry-Billings | Executive Chairman | — | — |
| Simon William Holden | Company Secretary | — | male |
| Marcin Mankowski | CMO & Head of Scientific Affairs | — | — |
| Gareth E. Walters | Chief Regulatory Officer | — | — |
| Jody Brookes | Senior Vice President & Head of Clinical Operations | — | female |
| Andy Lee | Finance Director | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SYGGF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
